

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)



(10) International Publication Number
WO 2022/218295 A1

(51) International Patent Classification:

C07C 215/14 (2006.01) A61K 9/00 (2006.01)
C07C 229/16 (2006.01) A61K 47/00 (2006.01)
C07C 237/10 (2006.01)

(21) International Application Number:

PCT/CN2022/086310

(22) International Filing Date:

12 April 2022 (12.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202110396368.4 13 April 2021 (13.04.2021) CN

(71) Applicant: CHENGDU WESTGENE BIOPHARM

CO., LTD [CN/CN]; GU, Yongjun, Chengdu Tianfu International Bio-Town, No.552 Fenghuang Road, Shuangliu District, Chengdu, Sichuan, China, Chengdu, Sichuan 610219 (CN).

(72) Inventors: SONG, Xiangrong; West China Campus of

Sichuan University, No. 17, Section 3, Renmin South Road, Wuhou District, Chengdu, Sichuan, Chengdu, Sichuan 610041 (CN). WEI, Xiawei; West China Campus of Sichuan University, No. 17, Section 3, Renmin South Road, Wuhou District, Chengdu, Sichuan, Chengdu, Sichuan 610041 (CN). WEI, Yuquan; West China Campus of Sichuan University, No. 17, Section 3, Renmin South Road, Wuhou District, Chengdu, Sichuan, Chengdu, Sichuan 610041 (CN).

(74) Agent: CHENGDU SANCHENG INTELLECTUAL

PROPERTY AGENCY (GENERAL PARTNERSHIP); ZHANG, Youmei, Room 709, 7/F, Unit 1, Building 2, No. 99, Jinhui West First Street, Chengdu High-Tech Zone, China (Sichuan) Pilot Free Trade Zone, Chengdu, Sichuan 610000 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: IONIZABLE LIPIDS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY



(57) Abstract: The present disclosure relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

WO 2022/218295 A1